New antibody drug aims to tackle kidney disease

NCT ID NCT06642909

Ongoing Disease control Sponsor: BioRay Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tests a new drug, zuberitamab, in 135 adults with primary membranous nephropathy, a kidney condition that causes protein leakage. Participants receive either zuberitamab (two doses two weeks apart) or the standard drug cyclosporine. The main goal is to see if zuberitamab reduces protein in urine better than cyclosporine after 76 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: zuberitamab (a monoclonal antibody)
What this could lead to: If successful, this could offer a new treatment option for primary membranous nephropathy, potentially reducing protein in urine and preserving kidney function.
What could go wrong: This is an early Phase 2 trial with only 135 participants, so results may not apply to everyone. The drug may not work better than cyclosporine, and side effects are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PRIMARY MEMBRANOUS NEPHROPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

idiopathic membranous glomerulonephritis membranous glomerulonephritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PRIMARY MEMBRANOUS NEPHROPATHY

Contacts and locations

Locations

Zhongshan Hospital Fudan University

Shanghai, Shanghai Municipality, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.